Clinical Trials

Accrual Status
Limit to SWOG Trials

1033 Results

Closed
Phase
Accrual
48%
Published
SWOG Clinical Trial Number
S0030
Closed
Phase
Accrual
81%
Published
Closed
Phase
Accrual
9%
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0124
Closed
Phase
Accrual
47%
SWOG Clinical Trial Number
S0114

An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers

Research Committee(s)
Immunomolecular Therapeutics
Activated
11-01-2002
Closed
06-01-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0213
Closed
Phase
Accrual
2%
Closed
Phase
Accrual
84%
Published
SWOG Clinical Trial Number
S0215
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
97%
Published
SWOG Clinical Trial Number
S0120
Closed
Phase
Accrual
88%
Published
SWOG Clinical Trial Number
S0127
Closed
Phase
Accrual
72%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0218
Closed
Phase
Accrual
77%
Published
SWOG Clinical Trial Number
S0211
Closed
Phase
Accrual
50%
Published
SWOG Clinical Trial Number
S0207

Phase II Study of Arsenic Trioxide in Male Patients with Refractory Germ Cell Malignancies

Research Committee(s)
Genitourinary Cancer
Activated
04-01-2002
Closed
03-01-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0119
Closed
Phase
Accrual
2%
Closed
Phase
Accrual
48%
Published